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Abstract
Hidradenitis suppurativa is a chronic inflammatory disorder characterized by occlusion of the fol-
licular pilosebaceous units of the skin. The treatment options are sometimes very limited and un-
pleasant odor and abundant drainage complicate the disease. Ankylosing spondylitis is a form of 
seronegative spondyloarthritis with predominantly axial but also peripheral joint involvement. Both 
of the conditions lower the patient’s quality of life and affect everyday activities.
We describe a 39-year-old male patient with both diseases treated with different medications with 
only a modest result. After the initiation of a tumor necrosis factor α (TNF-α) inhibitor (adalimumab) 
the patient experienced first the musculoskeletal and later on the skin improvement. The introduc-
tion of TNF-α inhibitors should be considered early in the treatment of overlapping hidradenitis 
suppurativa and the spondyloarthritis spectrum of conditions. Available medical data confirm the 
positive results and beneficial effect on disease course, activity and, most importantly, quality of life. 
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Introduction
Hidradenitis suppurativa (HS) also known as acne in-
versa, is a chronic, recurrent, inflammatory skin disease 
characterized by painful nodules, sinuses, abscesses, 
draining fistulas and scarring lesions occurring mainly in 
intertriginous areas of the axillas, groin, perianal, perine-
al and inframammary regions [1]. The prevalence of the 
disease is between 1–4% and it most commonly affects 
younger adults with a female predominance [2]. The risk 
factors associated with the onset and exacerbation of the 
disease are positive family history of the disease, obesity, 
smoking and mechanical friction [3]. The severity of HS 
can be classified with the Hurley classification [4] or Sar-
torius score [5, 6]. The diagnosis is primarily clinical and 
skin biopsy is rarely required [7]. Hidradenitis suppurativa 
is associated with several diseases such as inflammatory 
bowel disease, endocrine disorders, metabolic syndrome 
and spondyloarthropathies [8–15]. Treatment depends on 
clinical stage and includes non-pharmacologic, pharma-
cologic and surgical procedures [16]. General measures 
are local hygiene, weight reduction, smoking cessation, 
and avoidance of skin trauma. Pharmacologic treatment 
includes topical and systemic antibiotics, intralesional 
corticosteroids, hormonal therapy and biologic therapy 
(tumor necrosis factor α [TNF-α] inhibitors) [17, 18].
Ankylosing spondylitis (AS) is a form of seronega-
tive spondyloarthritis (SpA) and affects mostly younger 
male patients with predominantly axial but also periph-
eral joints and extra-articular involvement [19]. Anky-
losing spondylitis is associated with HLA B27 antigen 
and the prevalence of the disease is between 0.2 and 
1.2%. The disease is manifested by inflammatory back 
pain and prolonged spinal stiffness. It is worsened by 
rest and usually improved by the use of nonsteroidal 
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anti-inflammatory drugs (NSAIDs) and with activity. 
The Assessment of SpondyloArthritis International So-
ciety (ASAS) developed new criteria for classification of 
both axial and peripheral SpA. Diagnosis of AS is based 
upon a combination of clinical, laboratory and imaging 
findings [20]. Management includes physiotherapy, an-
algesics, NSAIDs and biologic therapy. Physiotherapy is 
the most important non-pharmacological treatment in 
AS. NSAIDs in anti-inflammatory doses relieve pain and 
stiffness. Tumor necrosis factor α blockers are indicated 
in patients after failure of conventional treatment [20].
Case presentation
A 39-year-old overweight (body mass index BMI – 40.3) 
man had a 20-year history of HS with skin lesions worsen-
ing over time. The HS was classified as stage III according 
to the Hurley classification [4]. The patient had previously 
been treated with topical and oral antibiotics with a partial 
clinical improvement, frequent recurrences and he often 
missed recommended dermatologic follow-ups. 
The patient’s medical history included progressive 
loss of vision for which he was admitted to the Ophthal-
mology unit and diagnosed with panuveitis of the right 
eye, intermediate uveitis of the left eye, retinal periphle-
bitis and periarteritis with secondary glaucoma. He had 
been treated with oral and topical glucocorticoids, cyclo-
plegic agents (mydriatics) and oral methotrexate with 
clinical improvement. A brain MRI revealed demyelinating 
lesions, cerebrospinal fluid examination was normal and 
oligoclonal bands were negative. The patient did not have 
further neurological deficits and diagnosis of multiple 
sclerosis was excluded.
In the period of the past few years the patient re-
ported low back pain and morning stiffness lasting 
Table I. Laboratory findings
Before the 
treatment 
with 
adalimumab 
Ten months 
after the 
introduction of 
adalimumab 
ESR (ref. 4–24 mm/h) 94 16
CRP (ref. < 5 mg/l) 126.8 10.5
WBC (ref. 3.4–9.7 × 109/l) 26.0 24.0
Hb (ref. 119–157 g/l) 116 142
Trc (ref. 158–424 × 109/l) 602 408
Routine biochemistry normal normal
RF, ACPA negative –
Complement levels normal –
ANA, ENA negative –
HLA typing B27 and DR4 
positive
–
Blood and urine culture sterile –
BASDAI (> 4 = active 
disease)
6.8 2.0
BASFI 
(> 4 = impaired function)
5.7 2.2
DLQI 22
(extremely 
large burden on 
patient’s life)
7
(moderate  
burden on  
patient’s life)
ESR – erythrocyte sedimentation rate; CRP – C-reactive protein; 
WBC – white blood cells; Hb – haemoglobin; Trc – thrombocytes; 
RF – rheumatoid factor; ACPA – anti-citrullinated peptide antibody; 
HLA – human leukocyte antigen; ANA – antinuclear antibodies, ENA 
– extractable nuclear antigens; BASDAI – Bath Ankylosing Spon-
dylitis Disease Activity Index; BASFI – Bath Ankylosing Spondylitis 
Function Index; DLQI – dermatology life quality index
Fig. 1. Patient before the treatment with adalimumab.
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more than one hour. He was hospitalized due to pro-
longed low grade fever, fatigue, loss of body weight and 
worsening of HS. He presented with multiple painful in-
flamed draining nodules, fistulas and hypertrophic scars 
on the neck, trunk, axillary, inguinal, scrotal and sacral-
regions (Fig. 1). Blood examinations revealed elevated 
acute phase reactants with impaired full blood count 
(Table I). Blood and urine culture came back negative. 
The patient was seronegative (RF, ACPA, ANA/ENA) with 
normal levels components of complement (C3 and C4) 
and negative tests for coeliac disease with the presence 
of HLA-B27 and HLA-DR4 positivity. Further work-up 
excluded lymphoproliferative disorders and endoscopy 
proved no inflammatory bowel disease. Radiography of 
the spine and sacroiliac joints was conclusive for inflam-
matory changes and the patient was diagnosed with 
HLA-B27 positive AS without peripheral arthritis.
The patient was treated with a low dose of system-
ic glucocorticoids, full dose of NSAIDs and antibiotics 
with clinical improvement of inflammatory back pain 
and skin findings with normalization of acute phase 
reactants. At the first follow-up visit, the patient was 
feeling good with partial skin improvement and without 
pain, fever and neurological deficits. For the next three 
months he continued therapy with NSAIDs and reduced 
dosage of glucocorticoids, but despite this therapy he 
relapsed (primarily with symptoms of inflammatory 
back pain – BASDAI 6.8, BASFI 5.7 and elevated acute 
phase reactants). Due to high AS activity and an inade-
quate response to previous therapy, TNF-α inhibitor was 
introduced. The patient had no signs of latent tubercu-
losis and hepatitis serology came back negative so he 
received the first subcutaneous injection of adalimumab 
and continued 40 mg every other week. Two months lat-
er, the patient reported significant improvement of both 
AS and HS. He had minimal back pain, an better mobility 
without morning stiffness (BASDAI 2.0; BASFI 2.2). His 
HS has improved with a decrease in drainage from old 
lesions and a decrease in the formation of new lesions 
(Fig. 2). One year after the first adalimumab application 
the patient continues to have low disease activity of 
both diseases, low acute phase reactants (Table I) with 
no adverse reactions occurring during the treatment.
Discussion
The pathogenesis of HS is very complex and includes 
follicular occlusion, follicular rupture and an associated 
immune response. In the end the overall inflammatory 
process is seen as nodules, scarring tissue and draining 
sinuses and fistulas. The cytokines that drive inflam-
mation in HS are TNF-α, interleukin 1β (IL-1β), IL-17 and 
IL-23 [21, 22].
The sequence of structural damage in spondyloarthri-
tis consists of inflammation which leads to erosive bone 
destruction and replacement by repair tissue and finally 
to osteoproliferation with formation of syndesmophytes 
which is seen as irreparable damage of the patient’s axial 
and sometimes peripheral skeleton. The process of inflam-
mation is driven by proinflammatory cytokines including 
the most important TNF-α and also IL-17 and IL-23.
Tumor necrosis factor α is one of the connecting 
features of both diseases and serves as a cell signaling 
protein involved in systemic inflammation. Inhibition of 
this proinflammatory cytokine can lead to a benefit [23].
The patient we described suffered from HS and AS, 
both diseases equally disabling his everyday life activ-
ities and work. He underwent dermatologic and rheu-
Fig. 2. Patient 10 months after the first adalimumab application.
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matologic check-ups and during the latter course of the 
diseases had more pronounced signs and symptoms 
of ankylosing spondylitis. Elevated acute phase reac-
tants, inflammatory back pain and high disease activity 
indices were the reasons for the introduction of TNF-α 
inhibitor. After the careful screening for the active and 
latent infections the patient received first application 
of adalimumab according to the rheumatology regimen 
– 40 mg every other week. The recommended dose of 
adalimumab for adult patients with moderate to severe 
HS is an initial dose of 160 mg at week 0, 80 mg at week 
2, and 40 mg every week starting at week 4 [17, 24].
The patient experienced a significant improvement 
of spondyloarthritis features but also HS skin lesions 
ameliorated despite the lower dosing regimen of adali-
mumab. The dermal changes did not completely disap-
pear, but with the discontinuation of the inflammatory 
process the skin changes stopped producing unpleasant 
odor and secretion. The patient-reported outcome ques-
tionnaires and other measures improved significantly.
Adverse events in patients receiving adalimumab 
can be serious, but are not common taking into account 
its wide usage in rheumatological and ophthalmic in-
dications. The most frequent infections include tuber-
culosis (primarily reactivation) and infections caused 
by viruses, fungi, or bacteria and also lymphoma, solid 
tissue cancers, cardiac failure and demyelinating central 
and peripheral nervous system disorders [25], so the pa-
tients should be monitored very carefully.
The current medical literature reports the effec-
tiveness and desirability of treating HS with biological 
agents that inhibit TNF-α especially adalimumab and in-
fliximab [26], but also others such as anakinra (anti-IL-1) 
[27] and ustekinumab (directed against IL-12 and IL-23) 
[28] may be a promising treatment strategy. Neverthe-
less further investigations are needed.
Spondyloarthropathies and hidradenitis suppurativa 
are two diseases that significantly affect patients’  quali-
ty of life. BASDAI and BASFI are standard instruments for 
assessment of disease activity and efficacy of treatment 
of AS. The Dermatology Life Quality Index (DLQI) is an in-
strument used to measure the impact of skin disease on 
the quality of life of an affected person [30]. Treatment 
with TNF-α blockers improves both BASDAI, BASFI and 
DLQI [29, 30]. 
Summary
Timely introduction of targeted cytokine therapy can 
lead to the improvement of objective signs and symp-
toms of the hidradenitis suppurativa and ankylosing 
spondylitis as well as of the patient-reported outcome 
measures. Treatment strategy and dosing regimen 
should be tailored according to the more predominant 
features of the overlapping diseases. Although TNF-α in-
hibition brought overall improvement of both skin and 
musculoskeletal symptoms in the described patient sev-
eral issues remain to be tackled. Optimal concomitant 
therapy in the overlapping disease (perhaps one of the 
DMARDs) and its effect on immunogenicity of the TNF-α 
inhibitor are unknown. The duration of TNF-α inhibition 
therapy when a patient reaches remission or low dis-
ease activity is one of the unsolved issues. Future case-
based and similar studies of overlapping HS and AS 
should help in the approach to the mentioned problems.
The authors declare no conflict of interest.
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